Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, (National Health Commission (NHC) Key Laboratory of Health Economics and Policy Research, Shandong University), Jinan 250012, China.
Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou 310058, China.
Int J Environ Res Public Health. 2020 Dec 11;17(24):9285. doi: 10.3390/ijerph17249285.
Quantifying economic and clinical outcomes for interventions could help to reduce third-generation cephalosporin resistance and or . We aimed to compare the differences in clinical and economic burden between third-generation cephalosporin-resistant (3GCREC) and third-generation cephalosporin-susceptible (3GCSEC) cases, and between third-generation cephalosporin-resistant (3GCRKP) and third-generation cephalosporin-susceptible (3GCSKP) cases. A retrospective and multicenter study was conducted. We collected data from electronic medical records for patients who had clinical samples positive for or isolates during 2013 and 2015. Propensity score matching (PSM) was conducted to minimize the impact of potential confounding variables, including age, sex, insurance, number of diagnoses, Charlson comorbidity index, admission to intensive care unit, surgery, and comorbidities. We also repeated the PSM including length of stay (LOS) before culture. The main indicators included economic costs, LOS and hospital mortality. The proportions of 3GCREC and 3GCRKP in the sampled hospitals were 44.3% and 32.5%, respectively. In the two PSM methods, 1804 pairs and 1521 pairs were generated, and 1815 pairs and 1617 pairs were obtained, respectively. Compared with susceptible cases, those with 3GCREC and 3GCRKP were associated with significantly increased total hospital cost and excess LOS. Inpatients with 3GCRKP were significantly associated with higher hospital mortality compared with 3GCSKP cases, however, there was no significant difference between 3GCREC and 3GCSEC cases. Cost reduction and outcome improvement could be achieved through a preventative approach in terms of both antimicrobial stewardship and preventing the transmission of organisms.
量化干预措施的经济和临床结果有助于降低第三代头孢菌素耐药率和/或。我们旨在比较第三代头孢菌素耐药(3GCREC)和第三代头孢菌素敏感(3GCSEC)病例、第三代头孢菌素耐药(3GCRKP)和第三代头孢菌素敏感(3GCSKP)病例之间的临床和经济负担差异。进行了一项回顾性和多中心研究。我们从 2013 年至 2015 年期间有临床样本对 或 分离株阳性的电子病历中收集数据。采用倾向评分匹配(PSM)来最小化潜在混杂变量的影响,包括年龄、性别、保险、诊断数量、Charlson 合并症指数、入住重症监护病房、手术和合并症。我们还重复了包括培养前住院时间(LOS)的 PSM。主要指标包括经济成本、LOS 和医院死亡率。采样医院中 3GCREC 和 3GCRKP 的比例分别为 44.3%和 32.5%。在两种 PSM 方法中,分别生成了 1804 对和 1521 对,分别获得了 1815 对和 1617 对。与敏感病例相比,3GCREC 和 3GCRKP 与总住院费用显著增加和 LOS 过长相关。与 3GCSKP 病例相比,3GCRKP 住院患者的医院死亡率显著升高,但 3GCREC 与 3GCSEC 病例之间无显著差异。通过抗菌药物管理和预防病原体传播的预防性方法,可以实现成本降低和改善结果。